Rhythm May Have Data To Add Indication To Imcivree’s Label
Executive Summary
Drug already approved for multiple rare genetic disorders of obesity shows significant weight-loss reduction in Bardet-Beidl syndrome, but not in the smaller indication of Alström syndrome.
You may also be interested in...
Rhythm Leans On Imcivree Rare Disease Commercialization For New Indication
The company got FDA approval for the drug in Bardet-Biedl syndrome, on top of the existing approval from November 2020 in obesity due to POMC, PCSK1 and LEPR deficiency.
Rhythm Applies Oncology-Like Approach To Genetic Obesity
CEO David Meeker spoke with Scrip about how the company is targeting its drug, Imcivree, across potentially dozens of rare genetic diseases of obesity.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.